AorTech International plc Increases Again; Strong Momentum for Buyers

 AorTech International plc Increases Again; Strong Momentum for Buyers

The stock of AorTech International plc (LON:AOR) is a huge mover today! The stock increased 29.21% or GBX 5.55 on November 11, hitting GBX 24.55. About 34,353 shares traded hands or 678.10% up from the average. AorTech International plc (LON:AOR) has 0.00% since April 14, 2016 and is . It has underperformed by 6.15% the S&P500.
The move comes after 6 months positive chart setup for the GBX 1.40M company. It was reported on Nov, 11 by Barchart.com. We have GBX 58.67 PT which if reached, will make LON:AOR worth GBX 1.95 million more.

More notable recent AorTech International plc (LON:AOR) news were published by: Businesswire.com which released: “Research and Markets: Prosthetic Heart Valves – Pipeline Review, 2015” on June 25, 2015, also Businesswire.com with their article: “Global Bioprosthetics Market Worth USD 6.41 Billion by 2024 – Analysis …” published on October 05, 2016, Medgadget.com published: “Europe Medical Electronics Market Report 2016: Abbott vascular devices …” on October 18, 2016. More interesting news about AorTech International plc (LON:AOR) were released by: Prnewswire.com and their article: “Global Interventional Cardiology Market (Devices, Technology) Trends and …” published on July 03, 2014 as well as Globenewswire.com‘s news article titled: “Inferior Vena Cava (IVC) Filters – Global Trends, Estimates and Forecasts …” with publication date: December 12, 2014.

AorTech International plc is a biomaterials and medical device intellectual property company. The company has a market cap of 1.40 million GBP. The Firm is focused on the commercialization of its biomedical polymer technology, components and medical devices. It currently has negative earnings. The Firm has developed biostable, implantable polymers, including Elast-Eon and ECSil, which are long-term implantable co-polymers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment